Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study

Overview of attention for article published in Annals of Hematology, September 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 1 news outlet

twitter: 1 X user

Citations

dimensions_citation: 16 Dimensions

Readers on

mendeley: 49 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 14,865 followers.

Analysis of ELOQUENT2 data shows that improvements in progression-free survival and response rate with #Empliciti are achieved without detriment to health related quality of life in #myeloma patients: https://t.co/mTdPT1CEap. https://t.co/0JwVS8zpVr

Reply Repost Favourite